The new frontier of drug delivery through nanotechnology

Abstract

Nanomedicine is a promising platform for drug delivery systems, offering enhanced therapeutic outcomes and reduced side effects. Nanomicelles are a class of nanoparticles that have shown great potential in delivering a wide range of therapeutics, including small molecules, proteins, and nucleic acids, to treat varied diseases and investigations. This review summarises the current state of the art in nanomedicine and its potential applications in drug delivery system. The use of Nanomicelles in topical medication delivery systems can help minimized side effects and improve patient compliance due to their improved stability and prolonged drug release capabilities. The development of stimuli-responsive micelles that can release drugs at specific conditions within the tumour microenvironment and targeted delivery strategies to enhance specificity and efficiency of gene therapy has shown promising results in terms of improved therapeutic efficacy and therapeutic efficiency. However, the presence of multidrug resistance pumps in brain cells can pose challenges in overcoming MDR mechanisms for certain drugs. These innovative approaches hold promise for enhancing the effectiveness of cancer chemotherapy in the brain and improving the prognosis for patients with brain tumours.

Keywords

Nanotechnology / Nanoparticles / And nanomicelles

References

[1] Nance E . Careers in nanomedicine and drug delivery. Adv Drug Deliv Rev. 2019; 144: 180- 189.

[2] Sahay G . NanoDDS 2018: engineering the next wave of nanomedicine and drug delivery systems. Adv Drug Deliv Rev. 2019; 144: 1- 2.

[3] Zhang F , Xu Z , Jolly KJ . Myeloid cell-mediated drug delivery: from nanomedicine to cell therapy. Adv Drug Deliv Rev. 2023; 197: 114827.

[4] Suri GS , Kaur A , Sen T . A recent trend of drug-nanoparticles in suspension for the application in drug delivery. Nanomedicine. 2016. https://doi.org/10.2217/nnm-2016-0238.

[5] Rubey KM , Brenner JS . Nanomedicine to fight infectious disease. Adv Drug Deliv Rev. 2021; 179: 113996.

[6] Dureja H . Anticancer drug-loaded nanoparticulate drug delivery. Current Nanomedicine. 2019;9. https://doi.org/10.2174/246818730901190315092132, 3–3.

[7] Cheng X . Developing organic and inorganic nanomedicine for cancer therapy. J Drug Deliv Therapeut. 2017;7. https://doi.org/10.22270/jddt.v7i2.1367.

[8] Guo J , Huang L . Membrane-core nanoparticles for cancer nanomedicine. Adv Drug Deliv Rev. 2020; 156: 23- 39.

[9] Fattal E , Fay F . Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. Adv Drug Deliv Rev. 2021; 175: 113809.

[10] Stapleton S , Jaffray D , Milosevic M . Radiation effects on the tumor microenvironment: implications for nanomedicine delivery. Adv Drug Deliv Rev. 2017; 109: 119- 130.

[11] N A . A review on nanomedicine as a modern form of drug delivery. Global J. Nanomed. 2017;2. https://doi.org/10.19080/gjn.2017.02.555578.

[12] Maiti P . Drug-delivery vehicles and their efficiency toward cancer treatment. Nanomedicine. 2020;15:1637–1640. https://doi.org/10.2217/nnm-2020-0152.

[13] Fowler MJ , Cotter JD , Knight BE , Sevick-Muraca EM , Sandberg DI , Sirianni RW . Intrathecal drug delivery in the era of nanomedicine. Adv Drug Deliv Rev. 2020; 165–166:77–95. https://doi.org/10.1016/j.addr.2020.02.006.

[14] Shen Y , Bae YH . Tumour extravasation of nanomedicine: the EPR and alternative pathways. Adv Drug Deliv Rev. 2023; 194: 114707.

[15] Peer D . Drug-delivery research and much more: interview with Dan Peer. Nanomedicine. 2023;18:649–652. https://doi.org/10.2217/nnm-2023-0121.

[16] Viswanadh MK , Muthu MS . Targeted bioadhesive nanomedicine: an effective approach for synergistic drug delivery to cancers. Nanomedicine. 2018;13: 1401–1403. https://doi.org/10.2217/nnm-2018-0114.

[17] Iyer AK , Singh A , Ganta S , Amiji MM . Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013; 65: 1784- 1802.

[18] Gabizon AA , de Rosales RTM , La-Beck NM . Translational considerations in nanomedicine: the oncology perspective. Adv Drug Deliv Rev. 2020; 158: 140- 157.

[19] El-Boubbou K . Magnetic iron oxide nanoparticles as drug carriers: preparation, conjugation and delivery. Nanomedicine. 2018;13:929–952. https://doi.org/10.2217/nnm-2017-0320.

[20] Landriscina A , Rosen J , Friedman AJ . Biodegradable chitosan nanoparticles in drug delivery for infectious disease. Nanomedicine. 2015; 10: 1609- 1619.

[21] Han G , Ghosh P , Rotello VM . Functionalized gold nanoparticles for drug delivery. Nanomedicine. 2007; 2: 113- 123.

[22] Oh Y-K , Huang J . Editorial: graphene-based materials in nanomedicine. Adv Drug Deliv Rev. 2016; 105: 107- 108.

[23] Zhu X . PLGA Nanomed. J. Drug Deliv. Therapeutics. 2017;7. https://doi.org/10.22270/jddt.v7i3.1452.

[24] Luo D . From biology to materials: engineering DNA and RNA for drug delivery and nanomedicine. Adv Drug Deliv Rev. 2010; 62: 591.

[25] Liu S . Epigenetics advancing personalized nanomedicine in cancer therapy. Adv Drug Deliv Rev. 2012; 64: 1532- 1543.

[26] Fillmore R . Third international nanomedicine and drug delivery symposium. Nanomed Nanotechnol Biol Med. 2006; 2: 49- 52.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).